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The molecular chaperone, heat shock protein gp96 (HSP-gp96), has been shown to have roles in the 
synthesis, processing and transport of tumor antigens. Therefore, the capacity for HSP-gp96 to induce 
dendritic cells (DCs), thymus-dependent lymphocytes (T lymphocytes), natural killer (NK) cells and 
cytotoxic T lymphocytes (CTLs) was investigated. Recombinant adenovirus (AD) containing HSP-gp96 
(AD-gp96), as well as gp96-peptide complex from the human leukemia cell lines, K562, HL-60 and U937, 
was prepared. Purified gp96-peptide complex was found to stimulate the proliferation of T lymphocytes, 
increase the activity of NK cells and CTLs and induce the secretion of cytokines, compared with AD-
gp96. In the latter case, levels of IFN-γ and TNF-α were found to increase and levels of IL-12(P70) and IL-
10 decreased. In combination, these results indicated that the gp96-peptide complexes derived from the 
tumor cells contributed to the activation of lymphocytes and increase the presentation of tumor antigen. 
Furthermore, the chaperone function of gp96 promoted the maturation of DCs, enhanced the antigen 
presention function of DCs and induced the secretion of cytokines by DCs. Therefore, gp96-peptide 
complex derived from the tumor cells potentially represents an immunization therapy for the elimination 
of residual leukemia cells. 
 





Leukemia is a malignant clonal disease in hematopoietic 
stem cells that is typically treated with chemotherapy and 
radiotherapy. However, these treatments are not been 
able to completely eliminate all leukemia cells from 
patients. In addition, transplantation of hematopoietic 
stem cells is also associated with a 30% recurrence rate. 
The ability to eliminate residual leukemia cells has there-
fore, been the focus of many studies in various countries. 
Currently, immunotherapy represents a promising approach 
for the treatment of leukemia.  
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weight of 96 kDa and has been shown to be a chaperone 
protein that localizes to the endoplasmic reticulum in 
eukaryotes (Qu et al., 1994; Linderoth et al., 2000; Zheng 
et al., 2001). HSP-gp96, also known as GRP94, shares 
50% sequence homology with heat shock protein 90 
(HSP90) and correspondingly, is a member of the HSP90 
family of proteins. HSP-gp96 has been shown to partici-
pate in the synthesis of tumor antigens, as well as their 
assembly, processing and transport. Therefore, HSP-
gp96 can act as a chaperone protein and stimulate T-
lymphocytes. In particular, the work by Tamura et al. 
(1997) has demonstrated that, HSP-gp96 is an effective 
treatment for lung cancer, colon adenocarcinoma, fibro-
sarcoma melanoma and spindle cell tumors induced by 
ultraviolet rays in rat models (Rivoltini et al., 2003; Hoos 





phase II clinical trial will include gp96-based vaccines for 
the treatment of melanoma and renal cell carcinomas 
(Castelli et al., 2004; Janetzki et al., 2000). However, 
independent of whether HSP-gp96 represents a tumor 
antigen, it is important to determine whether HSP-gp96 
has the capacity to stimulate cytotoxic T lymphocytes 
(CTLs) and facilitate the complete cure of leukemia 
patients.  
Therefore, the goal of this research was to compare the 
function of HSP-gp96 purified from three different 
leukemia cell lines. Specifically, the purified proteins were 
compared regarding their ability to stimulate lymphocytes, 
facilitate the transport of tumor antigen and enhance the 
transport of antigen and cytokine secretion in dendritic 
cells (DCs). In combination, these studies provide a foun-
dation for further investigation of HSP-gp96 as a target in 
an immunotherapy approach to cure leukemia.  
 
 




Leukemia cell lines K562, HL-60 and U937 were purchased from 
SIBCB (Shanghai institute of Biochemistry and Cell Biology). ConA-
Sepharose and ion exchange columns were purchased from 
Pharmacia (NS, USA). Molecular weight markers for SDS-PAGE 
and bovine serum albumin (BSA) were purchased from Zhongsan 
Biological Technology (Beijing, China). PHA (phytohaemagglutinin), 
ammonium persulfate and a-pyran-1-methyl mannose were 
purchased from Fluka (MO, USA). A monoclonal antibody against 
HSP-gp96 was purchased from Santa Cruz Biotech (CA, USA). 
Glycine, acrylamide and ammonium sulfate were purchased from 
Sigma (MO, USA). Cytokine kits for IL-12 (p70), IFN-γ, TNF-α and 
IL-10 were purchased from Boster Biological Technology, Limited 
(Wuhan, China). Flow cytometry reagents and antigens were pur-
chased from BD Pharmingen (Suzhou, China). LDH release kit was 
purchased from Promega Biological Technology (Shanghai, China). 
 
 
The construction of HSP-gp96 recombinant adenovirus (Ad-
gp96) 
 
The gene fragment of human gp96 was inserted into the p-shuttle 
CMV shuttle vector, BJ5183-AD-1, which was already converted to 
facilitate homologous recombination in thallus [the adenovirus (AD) 
framework plasmid, pAdEasy-1, had already been pre-converted]. 
Recombinant AD plasmids containing the correct sequence were 
linearized for the transfection of AD293 cells. Virus produced in 
AD293 cells was then concentrated using cesium chloride (CsCl) 
ultracentrifugation to produce high-titer recombinant AD-gp96. 
 
 
Isolation and characterization of gp96-leukemia antigen 
peptide complex 
 
Gp96-leukemia antigen peptide complexes were purified as 
previously described (Meng et al., 2002; Dai et al., 2003). Briefly, 
human leukemia cell strains, K562, HL-60 and U937, were infected 
with AD-gp96 at an MOI of 100. One week later, cells were lysed 
and centrifuged for 30 min at 2000 × g at 4°C. After the super-
natants were aspirated, samples were centrifuged for an additional 
15 min at 15000 × g at 4°C. After the supernatants were aspirated, 
the  samples  were precipitated using 50%, and then 70% saturated  




ammonium sulfate. The resulting precipitate was resuspended in 5 
times its volume in equilibrium liquid (20 mmol／L Tris-Cl, pH7.4; 
200 mmol／L NaCl; 2 mmol／L CaCl2, 2 mmol／L MgCl2), added 
into a concanavalin affinity column and eluted using 10% a-pyran-1-
methyl mannose. The eluant was then further purified using a 
DEAE ion-exchange column and eluted using a gradient of 300 to 
1000 mM NaCl. Fractions containing the gp96-leukemia antigen 
peptide complex were identified using 10% SDS-PAGE and 
western blot. Protein concentrations of the samples were deter-




The preparation and identification of T cells and DCs 
 
Conditions for the culture of DC cells have previously been 
described (Zhu et al., 2001; Tong et al., 2004; Tong et al., 2005; 
Tong et al., 2008). Briefly, peripheral blood mononuclear cells 
(PBMCs) were obtained from healthy volunteers and suspended 
into 5 ml culture flasks with RPMI1640 containing 10% fetal calf 
serum (FCS). After the cell concentration was adjusted to 1 × 10
6
 
cells/ml, it was incubated at 37°C with 5% CO2 for 2 h. Non-
adherent cells were collected as T cells and the adherent cells were 
treated with GM-CSF (500 U/ml) and IL-4 (500 U/ml) before been 
divided into two separate DC populations. Both cell populations 
were cultured for 7 days, with half of the growth media changed 
every 4 days. While one population of cells was stimulated with 
purified gp96-leukemia peptide complex (1 µg/ml) and the other 
was not, both cell groups were treated with 50 µg/ml TNF-α. On the 
10th day, suspension cells were collected. Direct immune-
fluorescence labeling of the cells was performed to phenotypically 




















 to identify the DCs present 





T cells (2 × 10
5
/100 ml) were inoculated into 96-well U-bottom 
tissue culture plates prior to the addition of purified gp96-peptide 
complex at three different concentrations (1, 2 and 5 µg/ml) in 
triplicate. After 5 days, 10 µl MTT (5 mg/ml) was added to each well 
and 4 days later, 100 µl DMSO was added. OD values at 550 nm 
were recorded using an ELISA plate reader (Multiscan MK3, Thermo 
Labsystems Oy, Finland) and the average values for each treatment 
group were reported. 
 
 
Detection of NK cell activity 
 
Conditions for the culture of NK cells have previously been descri-
bed (Naofumi Shinagawa et al., 2008). Target cells included K562, 
HL-60 and U937 cells at ratios of 20:1, 10:1 and 5:1 to NK cells 
stimulated with purified gp96-peptide complex at 1, 2 and 5 µg/ml. 
Control effector cells were untreated NK cells. LDH release was 
detected by colorimetry and the average of three experiments was 
taken as the result. 
 
 
Detection of CTL activity  
 
Conditions for the culture of CTLs have previously been described 
(Naofumi et al., 2008). CTL activity was assayed for T cells and 
DCs incubated with either purified gp96-leukemia peptide complex 
or tumor antigen peptide complex for 7 days. K562, HL-60 and 
U937  were  used as target cells in ratios of 40:1, 20:1, 10:1 and 5:1  






Figure 1. Characterization of the purified gp96-leukemia antigen peptide complexes. (A), 
Western blot of gp96-leukemia antigen peptide complexes from K562 cell; (B), K562 
leukemia cell proteins; (C), purified eluted fraction from K562 cell DEAE-sepharose anion 




to the effector cells. LDH release was detected by colorimetry and 





A sandwich ELISA method was used to detect the expression levels 
of IL-12, IFN-γ, TNF-α and IL-10 in the cell supernatants according 
to the manufacturer’s directions (Boster Biological Technology, 
Wuhan, China). Assays were performed in triplicate and the ave-





Data were presented as the average ± standard deviation ( s±x ). 
The statistical software, SPSS7.0, was used for all analyses, with 
comparisons between groups made using Student’s t-test. A P-





Isolation and effects of gp96-leukemia peptide 
complex on allogeneic normal T lymphocytes 
 
Gp96-leukemia antigen peptide complexes were purified 
from human leukemia cell strains, K562, HL-60 and U937 
that were infected with AD-gp96 (MOI = 100). Western 
blotting was used to confirm the size and purity of the 
isolated Gp96-leukemia antigen peptide complexes (Figure 
1).  To  confirm the function of the gp96-leukemia peptide 
complex isolated from the three different sources, T cells 
(2 × 10
5
/100 ml) were incubated with either purified gp96-
peptide complex at three different concentrations (1, 2 
and 5 µg/ml) or antigen peptide, in triplicate. After 5 days, 
MTT assays detected the proliferation of the treated T 
cells. Compared with the T cells incubated with antigen 
peptide, T cells incubated with the gp96-peptide comp-
lexes exhibited a marked increase in proliferation at each 
concentration, with the greatest difference in proliferation 
observed at the 5 µg/ml concentration (Figure 2). 
 
 
The influence of the gp96-leukemia peptide complex 
on NK cells 
 
To evaluate the effects of the gp96-leukemia peptide 
complex on NK cells, K562, HL-60 and U937 cells were 
incubated with NK cells at ratios of 20:1, 10:1 and 5:1 
respectively. Untreated NK cells were the control effector 
cells. Co-cultures were stimulated with 1, 2 and 5 µg/ml 
purified gp96-peptide complex. The result showed that, 
except that the results of gp96-leukemia peptide complex 
causing HL-60 and tumor antigen, peptide were not 
significantly different at the concentration of 2 µg/ml, 1 
µg/ml and E: T at 5:1 (P > 0.05). The NK cells activity 
stimulated by gp96-peptide complex causing other three 
leukemia cells with different concentration and at the E: T 
of 20:1, 10:1, 5:1 was noticeably higher than that of antigen 
peptide (P < 0.05). For example, gp96-peptide complex 
caused different leukemia cells and tumor antigen peptide  
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Figure 2. Proliferation assays of leukemia cell strains treated with purified gp96-peptide complexes. MTT assays were performed for: (A) K562 source GP96-leukemia 
antigen peptide complexes (gp96K-Pep) vs. K562 source antigen peptide (K-Pep), (B) HL-60 source GP96-leukemia antigen peptide complexes (gp96H-Pep) vs. HL-




with the concentration of 2 µg/ml and target cells 
in the ratio of 10:1 (Figure 3).  
 
 
The influence of the gp96-leukemia peptide 
complex on CTL activity  
 
The day 7 DCs expressed high levels of CD11c, 
HLA-DR, CD80 and CD86, showing the charac-
teristics of DCs. Cytoxicity was assayed for T cells 
and DCs incubated with either the purified gp96-
leukemia peptide complex or tumor antigen 
peptide complex for 7 days. K562, HL-60 and U937 
were used as the target cells in the ratios of 40:1, 
20:1, 10:1 and 5:1 to effector cells.  
The  result   showed   that   compared   with  the 
antigen peptide and except that the results of 
gp96-peptide complex originating U937 cells and 
tumor antigen were not significantly different when 
targeted: effector ratio was at 5:1 (p > 0.05). The 
gp96-peptide complex that caused different leuke-
mia cells noticeably increased CTL activity at 
ratios 40:1, 20:1, 10:1 and 5:1 (p < 0.05) (Figure 4). 
The dendritic cells stimulated by gp96-peptide 
complex causing HL-60 and U937 cells and tumor 
antigen peptide together with the dendritic cells 
were not significantly different at the ratio of 5:1 (P 
> 0.05). The CTL activity which was stimulated by 
the dendritic cells stimulated by gp96-peptide 
complexes causing different leukemia cells as 
target: effector ratios of 40:1, 20:1, 10:1, 5:1 was 
obviously   higher   than   that   stimulated   by  the  
tumor antigen (P < 0.05) (Figure 5). 
 
 
Cytokine expression by PBMCs and DCs 
treated with gp96-leukemia peptide complex  
 
Sandwich ELISAs were used to detect the expres-
sion levels of IL-12, IFN-γ, TNF-α and IL-10 in the 
cell supernatants of PBMCs and DCs that were 
cultured with and without K562, HL60 and U937 
cells expressing gp96-peptide complexes. Com-
pared with the untreated PBMCs and DCs, the 
presence of leukemia cell strains expressing 
varying levels of gp96-peptide complex was found 
to markedly improve the secretion of TNF-α, IL-
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Figure 3. The activity of NK cells assayed in the presence of gp96-peptide complexes. At an effector to target cell ratio of 10:1, NK cells were incubated 
with three different leukemia cell strains in the presence of 2 µg/mL gp96-peptide complexes or gp96 purified from AD-gp96 expression. NK cell activity for 
K562 (A), HL60 (B), and U937 (C) cells incubated with gp96-peptide complexes (i.e. gp96K-Pep, gp96H-Pep, and gp96U-Pep) vs. gp96 purified from AD-






Figure 4. Cytoxicity assays for T cells. CTLs were incubated with K562, HL60, and U937 cells in the presence of gp96-peptide complexes (gp96K-Pep, gp96H-Pep, 
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Figure 5. Cytoxicity assays for DCs. DCs were incubated with K562, HL60, and U937 cells in the presence of gp96-peptide complexes (DC-gp96K-Pep, DC-gp96H-Pep, and 




(p < 0.05). K562, HL60 and U937 cells expressed 
PBMCs-gp96-peptide complexes VS K562 and 
HL60 and U937 cells expressed PBMCs (p < 
0.05). K562, HL60 and U937 cells expressed 
DCs-gp96-peptide complexes VS K562 and HL60 
and U937 cells expressed DCs (P < 0.05). More-
over, the secretion of IL-12(P70) and IL-10 from 
DCs was distinctly less than that for PBMCs. In 
contrast, the secretion of IFN-γ and TNF-α were 





Similar to other types of tumors, leukemia is diffi-
cult to cure due to a residual number of cells that 
remain in a patient following treatment with 
chemotherapy or radiation. Even for patients who 
undergo      complete           remission      following 
chemotherapy and receive long-term consolidation 
chemotherapy, a chance for recurrence still exists 
even after allogenic bone marrow transplantation. 
Therefore, in addition to the optimization of 
existing treatment methods, the identification of a 
leukemia antigen that can effectively stimulate 
CTLs would be of significant value. In previous 
studies of solid tumors (Belli et al., 2002; 
Mazzaferro et al., 2003; Wang et al., 2000)
 
and 
other hematologic malignancies (Li, 1997; Oki and 
Younes, 2004), tumor-derived HSPs have been 
shown to generate tumor-specific immune res-
ponses. 
Therefore, HSP-gp96 was studied to evaluate 
its capacity to stimulate a CTL response. Com-
pared with AD-gp96, purified gp96-peptide complex 
was shown to remarkably improve the proliferation 
of allogeneic normal T lymphocytes and increase 
the  activity  of  both  NK  cells  and  CTLs.  As the 
tumor-derived protein was from patient's tumor 
tissue, it avoids virosis' introduction and spread of 
transforming DNA (Wierecky, 2006). However, in 
the leukemia immunization therapy, what are the 
advantages of 96-peptide complex compared with 
other tumor-derived protein? As a protein that is 
able to associate with various antigen peptides 
and display a variety of T cell epitopes, the gp96-
peptide complex has the capacity to activate 
many types of cytotoxic T cells. Accordingly, the 
immunogenicity of the gp96-peptide complex is 
more diverse and therefore, produces a stronger 
immune response than a single antigen. Further-
more, gp96 localizes to the surface of antigen 
presenting cells (APCs) and nanomolar levels of 
protein are sufficient to induce a CTL response. 
Correspondingly, the concentration of the immuni-
zation dose of gp96-peptide complexes would be 
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Figure 6. Cytokine-specific sandwich ELISAs. Cytokine expression by PBMCs and DCs in the presence or absence of gp96-peptide complexes purified 
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that, MHC class I restricted polypeptide epitopes can 
enhance an antigen-specific CTL response in the 
absence of adjuvant. However, the level of immune-
genicity associated with this approach is low, while the 
amount of epitope needed is high. As a result, increased 
toxicity has been associated with this strategy, making it 
unacceptable for clinical application (Audibert, 2003). In 
contrast, gp96 represents a vaccine that would not 
require adjuvant, thereby eliminating any additional 
opportunities for toxicity (Heike et al., 1999; Caudill and 
Li, 2001). 
DCs are well-characterized for being the most effective 
antigen presenting cell type in the immune system, 
although there is no evidence to indicate that DCs can 
directly target tumor cells (Gutether and Becher, 2007). 
However, the immune response mediated by T cells has 
been shown to play a key role in the anti-tumor defense 
of an organism. For example, DCs present antigen poly-
peptides for the sensitization, activation and amplification 
of T cells. DCs can also provide co-stimulatory signals to 
T cells. Therefore, overall DCs are a very useful component 
of the immune response, particularly as a stimulant of T 
cells (Srivastava et al., 1994; Levin et al., 1993). When 
DCs mature, they highly express MHC molecules and 
develop the capacity to provide co-stimulatory signals 
that result in an efficient antigen presenting ability. The 
differences among the cytokines secreted by Th cells can 
be divided into two cell subsets: Th1 and Th2. Th1 cells 
secrete IL-12, IFN-γ and TNF-α among others and mainly 
mediate an immune response. In contrast, Th2 cells 
secrete IL-4 and IL-10, as well as other cytokines to be 
involved in the humoral immunoresponse (HI) and 
mediate immune suppression. IL-12 is the cytokine of 
Th1, but P70 is a subunit functioning inhibition effect. In 
this study, the treatment of PBMCs and DCs with gp96-
peptide complexes induced the secretion of cytokines. 
Compared with PBMCs, DCs were found to secrete 
higher levels of TNF-α and IFN-γ and lower levels of IL-
12 (P70) and IL-10. These results suggest that, the gp96-
peptide complex owns stronger molecular chaperones, to 
promote the maturity of DCs, thereby enhancing a 
greater Th1 response and inhibiting Th2. Accordingly, 
stronger cytotoxicity was generated. 
Currently, a few clinical trials are investigating the use 
of gp96-peptide complexes as a treatment strategy for 
tumor patients. Previously, Janetzki et al. (2000)
 
performed 
pre-clinical studies with gp96-peptide complexes in a 
melanoma model and DCs were found to markedly 
increased CTL activity compared with antigen peptides. 
These results suggest that, the gp96-peptide complex, in 
coordination with DCs, can enhance the antigen pres-
enting role of DCs and significantly improve the ability of 
CTLs to target leukemia cells. In addition, the short half-
life of gp96-peptide complexes in combination with 
longer-lived DCs has the potential to capitalize on the 
favorable features of each component to generate a 
stronger anti-tumor immune response. 




In summary, the results of this study demonstrate that 
leukemia-derived gp96-peptide complexes play an 
important role in activating lymphocytes and increasing 
the presentation of tumor antigens by activated CTLs. 
Therefore, in combination with an increased secretion of 
cytokines, DCs stimulated with gp96-peptide complexes 
produced an overall stronger immune response towards 
leukemia cells. These results provide further support for 
the use of gp96 as an immunotherapy for the treatment of 
residual leukemia cells, where gp96-peptide complexes 
could be isolated from the patient’s own tumor to avoid 
the need for virus-mediated therapies and the trans-
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